1
|
Hatzipanagiotou ME, Pigerl M, Gerken M, Räpple S, Zeltner V, Hetterich M, Ugocsai P, Inwald EC, Klinkhammer-Schalke M, Ortmann O, Seitz S. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with early triple negative breast cancer. Breast Cancer Res Treat 2024; 204:607-615. [PMID: 38238552 PMCID: PMC10959785 DOI: 10.1007/s10549-023-07207-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2023] [Accepted: 11/29/2023] [Indexed: 03/24/2024]
Abstract
PURPOSE The optimal time to initiation of adjuvant chemotherapy (TTAC) for triple negative breast cancer (TNBC) patients is unclear. This study evaluates the association between TTAC and survival in TNBC patients. METHODS We conducted a retrospective study using data from a cohort of TNBC patients diagnosed between January 1, 2010 to December 31, 2018, registered in the Tumor Centre Regensburg was conducted. Data included demographics, pathology, treatment, recurrence and survival. TTAC was defined as days from primary surgery to first dose of adjuvant chemotherapy. The Kaplan-Meier method was used to evaluate impact of TTAC on overall survival (OS) and 5-year OS. RESULTS A total of 245 TNBC patients treated with adjuvant chemotherapy and valid TTAC data were included. Median TTAC was 29 days. The group receiving systemic therapy within 22 to 28 days after surgery had the most favorable outcome, with median OS of 10.2 years. Groups receiving systemic therapy between 29-35 days, 36-42 days, and more than 6 weeks after surgery had significantly decreased median survival, with median OS of 8.3 years, 7.8 years, and 6.9 years, respectively. Patients receiving therapy between 22-28 days had significantly better survival compared to those receiving therapy between 29-35 days (p = 0.043), and patients receiving therapy after 22-28 days also demonstrated significantly better survival compared to those receiving therapy after more than 43 days (p = 0.033). CONCLUSION Timing of adjuvant systemic therapy can influence OS in TNBC patients. Efforts should be made to avoid unnecessary delays in administering chemotherapy to ensure timely initiation of systemic therapy and optimize patient outcomes.
Collapse
Affiliation(s)
- Maria Eleni Hatzipanagiotou
- Department of Gynecology and Obstetrics, University Medical Centre Regensburg, Landshuterstraße 65, 93053, Regensburg, Germany.
| | - Miriam Pigerl
- Department of Gynecology and Obstetrics, University Medical Centre Regensburg, Landshuterstraße 65, 93053, Regensburg, Germany
| | - Michael Gerken
- Bavarian Cancer Registry, Regional Centre Regensburg, Bavarian Health and Food Safety Authority, Regensburg, Germany
| | - Sophie Räpple
- Department of Gynecology and Obstetrics, University Medical Centre Regensburg, Landshuterstraße 65, 93053, Regensburg, Germany
| | - Verena Zeltner
- Department of Gynecology and Obstetrics, University Medical Centre Regensburg, Landshuterstraße 65, 93053, Regensburg, Germany
| | - Madeleine Hetterich
- Department of Gynecology and Obstetrics, University Medical Centre Regensburg, Landshuterstraße 65, 93053, Regensburg, Germany
| | - Peter Ugocsai
- Department of Gynecology and Obstetrics, University Medical Centre Regensburg, Landshuterstraße 65, 93053, Regensburg, Germany
| | - Elisabeth Christine Inwald
- Department of Gynecology and Obstetrics, University Medical Centre Regensburg, Landshuterstraße 65, 93053, Regensburg, Germany
| | - Monika Klinkhammer-Schalke
- Tumor Center Regensburg - Centre for Quality Management and Health Services Research, University of Regensburg, Regensburg, Germany
| | - Olaf Ortmann
- Department of Gynecology and Obstetrics, University Medical Centre Regensburg, Landshuterstraße 65, 93053, Regensburg, Germany
| | - Stephan Seitz
- Department of Gynecology and Obstetrics, University Medical Centre Regensburg, Landshuterstraße 65, 93053, Regensburg, Germany
| |
Collapse
|
2
|
Kong JE, Ong SK, Leong E, Naing L. Survival Analysis of Lung Cancer patients in Brunei Darussalam. Asian Pac J Cancer Prev 2023; 24:2389-2396. [PMID: 37505771 PMCID: PMC10676501 DOI: 10.31557/apjcp.2023.24.7.2389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2023] [Accepted: 07/08/2023] [Indexed: 07/29/2023] Open
Abstract
BACKGROUND Cancer has been the most common cause of deaths in Brunei Darussalam including lung cancer as one of the top killers. This study presents the survival analysis of primary lung cancer patients in Brunei Darussalam. METHODS This is a retrospective cohort study of a 15-year period (2002-2016) involving 797 primary lung cancer cases. De-identified data extracted from Brunei Darussalam Cancer Registry was analyzed using Kaplan-Meier method and log-rank test. Bonferroni corrections were performed. RESULTS 6 months, 1-year, 3-year, 5-year survival rates of lung cancer patients were 62.2%, 51.0%, 38.0% and 34.7% respectively. The median survival time was 12.4 months (95% Cl: 9.2, 15.7). Patients diagnosed 2002-2006 had significant longer survival than patients diagnosed 2007-2011 (p=0.039) and those diagnosed 2011-2016 (p<0.001). Survival time of patients diagnosed 2007-2011 was significantly longer than patients diagnosed 2012-2016 (p=0.049). Patients with localised disease had significantly longer survival time than patients with regional involvement (p<0.001) and distal site involvement (p<0.001). Patients with distal disease had significantly poorer survival rate than patients with regional involvement (p<0.001). Patients aged 50 or above had significantly shorter survival time than patients diagnosed at age 40-49 (p=0.003). There was no significant difference between survival time of other demographic characteristics. CONCLUSIONS The median survival time for lung cancer patients in this study was 12.4 months. Early diagnosis, early stage of cancer, and younger age were associated with longer survival time among lung cancer patients in Brunei Darussalam.
Collapse
Affiliation(s)
- Jia En Kong
- PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Jalan Tungku Link, Bandar Seri Begawan, Brunei Darussalam.
| | - Sok King Ong
- PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Jalan Tungku Link, Bandar Seri Begawan, Brunei Darussalam.
- Non-Communicable Disease (NCD) Prevention Unit, Ministry of Health, Commonwealth Drive, Bandar Seri Begawan, Brunei Darussalam.
| | - Elvynna Leong
- Faculty of Science, Universiti Brunei Darussalam, Jalan Tungku Link, Bandar Seri Begawan, Brunei Darussalam.
- Institute of Applied Data Analytics, Universiti Brunei Darussalam, Jalan Tungku Link, Bandar Seri Begawan, Brunei Darussalam.
| | - Lin Naing
- PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Jalan Tungku Link, Bandar Seri Begawan, Brunei Darussalam.
| |
Collapse
|
3
|
Mafra A, Bardot A, Charvat H, Weiderpass E, Soerjomataram I, Fregnani JHTG. Cancer survival in the northwestern of São Paulo State, Brazil: A population-based study. Cancer Epidemiol 2023; 83:102339. [PMID: 36863216 DOI: 10.1016/j.canep.2023.102339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2022] [Revised: 12/26/2022] [Accepted: 02/10/2023] [Indexed: 03/04/2023]
Abstract
BACKGROUND Population-based cancer registry (PBCR) data provide crucial information for evaluating the effectiveness of cancer services and reflect prospects for cure by estimating population-based cancer survival. This study provides long-term trends in survival among patients diagnosed with cancer in the Barretos region (São Paulo State, Brazil). METHODS In this population-based study, we estimated the one- and five-year age-standardized net survival rates of 13,246 patients diagnosed with 24 different cancer types in Barretos region between 2000 and 2018. The results were presented by sex, time since diagnosis, disease stage, and period of diagnosis. RESULTS Marked differences in the one- and five-year age-standardized net survival rates were observed across the cancer sites. Pancreatic cancer had the lowest 5-year net survival (5.5 %, 95 %CI: 2.9-9.4) followed by oesophageal cancer (5.6 %, 95 %CI: 3.0-9.4), while prostate cancer ranked the best (92.1 %, 95 %CI: 87.8-94.9), followed by thyroid cancer (87.4 %, 95 %CI: 69.9-95.1) and female breast cancer (78.3 %, 95 %CI: 74.5-81.6). The survival rates differed substantially according to sex and clinical stage. Comparing the first (2000-2005) and last (2012-2018) periods, cancer survival improved, especially for thyroid, leukemia, and pharyngeal cancers, with differences of 34.4 %, 29.0 %, and 28.7 %, respectively. CONCLUSION To our knowledge, this is the first study to evaluate long-term cancer survival in the Barretos region, showing an overall improvement over the last two decades. Survival varied by site, indicating the need for multiple cancer control actions in the future with a lower burden of cancer.
Collapse
Affiliation(s)
- Allini Mafra
- Population-based Cancer Registry of Barretos Region, Barretos Cancer Hospital, Pio XII Foundation, Barretos, 14784-400 Sao Paulo, Brazil; Cancer Surveillance Branch, International Agency for Research on Cancer, 25 Avenue Tony Garnier, 69007 Lyon, France.
| | - Aude Bardot
- Cancer Surveillance Branch, International Agency for Research on Cancer, 25 Avenue Tony Garnier, 69007 Lyon, France.
| | - Hadrien Charvat
- Cancer Surveillance Branch, International Agency for Research on Cancer, 25 Avenue Tony Garnier, 69007 Lyon, France.
| | - Elisabete Weiderpass
- Director's Office, International Agency for Research on Cancer, 25 Avenue Tony Garnier, 69007 Lyon, France.
| | - Isabelle Soerjomataram
- Cancer Surveillance Branch, International Agency for Research on Cancer, 25 Avenue Tony Garnier, 69007 Lyon, France.
| | - José Humberto Tavares Guerreiro Fregnani
- Population-based Cancer Registry of Barretos Region, Barretos Cancer Hospital, Pio XII Foundation, Barretos, 14784-400 Sao Paulo, Brazil; Superintendence of Education and Research, A.C. Camargo Cancer Center, São Paulo 01525-001, Brazil.
| |
Collapse
|
4
|
Sugiyama H, Konda M, Saika K, Trama A, Matsuda T. Increased incidence of rare cancers and varied age distributions by cancer group: A population-based cancer registry study in Hiroshima Prefecture, Japan. Cancer Epidemiol 2023; 83:102336. [PMID: 36780834 DOI: 10.1016/j.canep.2023.102336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2022] [Revised: 01/30/2023] [Accepted: 02/04/2023] [Indexed: 02/13/2023]
Abstract
BACKGROUND Epidemiological characteristics of many types of rare cancers are limited especially in Asia. Therefore, this study aimed to describe the burden and changing time trends of rare cancers in Hiroshima, Japan. METHODS The internationally agreed RARECAREnet list of rare cancers was used to identify patients diagnosed with cancers from 2005 to 2015 who were registered in the Hiroshima Prefecture Cancer Registry. Quality indicators specific to rare cancers were assessed by cancer grouping. Crude incidence rates (IRs) and age-standardized rates (ASRs) were calculated for 216 single cancers (rare and common) included in the list. A joinpoint regression was used to analyze age distribution and time trends in the ASRs for 12 internationally agreed rare cancer families. Quality indicators, ASRs, and IRs in Japan were identified to examine IR differences and the effects on data accuracy. RESULTS The 231,328 cases were used to calculate the IRs of each cancer. Epithelial tumors in rare families increased with age, but nonepithelial tumors occurred at any age. The proportion of rare cancer families to total cancers was stable. The time trend for families of head and neck cancers (annual percent change and 95 % confidence interval: 2.4 %; 1.2-3.7 %), neuroendocrine tumors (6.6 %; 5.1-8.1 %), and hematological cancers (4.3 %; 3.2-5.5 %) markedly increased. CONCLUSION The ASRs of several rare cancers increased because of increased knowledge of these diseases, improved diagnostic techniques, and aggressive diagnoses.
Collapse
Affiliation(s)
- Hiromi Sugiyama
- Department of Epidemiology, Radiation Effects Research Foundation, 5-2, Hijiyama Park, Minami-ku, Hiroshima City, Hiroshima 732-0815, Japan.
| | - Manami Konda
- Department of Epidemiology, Radiation Effects Research Foundation, 5-2, Hijiyama Park, Minami-ku, Hiroshima City, Hiroshima 732-0815, Japan.
| | - Kumiko Saika
- Division of International Health Policy Research, Institution for Cancer Control, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
| | - Annalisa Trama
- Research Department, Fondazione IRCSS, Istituto Nazionale dei Tumouri, Via Venezian 1, 20133, Milan, Italy.
| | - Tomohiro Matsuda
- Division of International Health Policy Research, Institution for Cancer Control, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
| |
Collapse
|
5
|
Tanaka R, Sugiyama H, Saika K, Matsuzaka M, Sasaki Y. Difference in net survival using regional and national life tables in Japan. Cancer Epidemiol 2022; 81:102269. [PMID: 36182832 DOI: 10.1016/j.canep.2022.102269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2022] [Revised: 09/21/2022] [Accepted: 09/24/2022] [Indexed: 11/30/2022]
Abstract
BACKGROUND National life table is commonly used for estimating cancer net survival. However, the national life table does not reflect condition of people in local area accurately, because there are disparities in cancer mortality rates among the local area in many cases. We investigated magnitude of difference in cancer net survival using the local area in Japan and Japanese life tables. METHODS We analyzed data from 32,942 cancer patients diagnosed between 2010 and 2012 in Aomori prefecture, Japan. Expected survival rates in Aomori (ESA) and Japan (ESJ) were estimated based on the life table of each area. Five-year net survival rates using ESA and the ESJ were estimated using the Pohar-Perme method. RESULTS The difference between net survival rates using the ESA (NSA) and the ESJ (NSJ) were larger than in men (0.3-3.0%) than in women (0.1-0.8%). The largest difference in the net survival rate was observed in prostate cancer patients, because the difference in the expected survival in oldest old men was remarkable. CONCLUSION Two factors affected the difference in the net survival rates resulting from the sensitivity analysis. The difference was larger (1) among older patients or (2) with a longer observation period (person-years).
Collapse
Affiliation(s)
- Rina Tanaka
- Department of Medical Informatics, Hirosaki University Graduate School of Medicine, Japan.
| | - Hiromi Sugiyama
- Department of Epidemiology, Radiation Effects Research Foundation, Japan
| | - Kumiko Saika
- Department of Medical Informatics, Hirosaki University Graduate School of Medicine, Japan; Saku Central Hospital Advanced Care Cente, Japan
| | - Masashi Matsuzaka
- Clinical Research Support Center, Hirosaki University Hospital, Japan; Department of Medical Informatics, Hirosaki University Hospital, Japan
| | - Yoshihiro Sasaki
- Department of Medical Informatics, Hirosaki University Graduate School of Medicine, Japan; Department of Medical Informatics, Hirosaki University Hospital, Japan
| |
Collapse
|
6
|
Matz M, Gamkrelidze A, Mebonia N, Kereselidze M, Kazanjan K, Zhizhilashvili S, Atun R, Coleman MP, Allemani C. Survival from five common cancers in Georgia, 2015-2019 (CONCORD). Cancer Epidemiol 2022; 79:102190. [PMID: 35696766 DOI: 10.1016/j.canep.2022.102190] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2021] [Revised: 05/09/2022] [Accepted: 05/13/2022] [Indexed: 11/19/2022]
Abstract
BACKGROUND Population-based cancer survival is a key metric of the effectiveness of health systems in managing cancer. Data from population-based cancer registries are essential for producing reliable and robust cancer survival estimates. Georgia established a national population-based cancer registry on 1 January 2015. This is the first analysis of population-based cancer survival from Georgia. METHODS Data were available from the national cancer registry for 16,359 adults who were diagnosed with a cancer of the stomach, colon, rectum, breast (women) or cervix during 2015-2019. We estimated age-specific and age-standardised net survival at one, two and three years after diagnosis for each cancer, by sex. RESULTS The data were of extremely high quality, with less than 2% of data excluded from each dataset. For the patients included in analyses, at least 80% of the tumours were microscopically verified. Age-standardised three-year survival from stomach cancer was 30.6%, similar in men and women. For colon cancer, three-year survival was 60.1%, with survival 4% higher for men than for women. Three-year survival from rectal cancer was similar for men and women, at 54.7%. For women diagnosed with breast cancer, three-year survival was 84.4%, but three-year survival from cervical cancer was only 67.2%. CONCLUSION Establishment of a national cancer registry with obligatory cancer registration has enabled the first examination of population-based cancer survival in Georgia. Maintenance of the registry will facilitate continued surveillance of both cancer incidence and survival in the country.
Collapse
Affiliation(s)
- Melissa Matz
- Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
| | - Amiran Gamkrelidze
- Chronic Disease Division, National Center for Disease Control and Public Health, Tbilisi, Georgia
| | - Nana Mebonia
- Chronic Disease Division, National Center for Disease Control and Public Health, Tbilisi, Georgia; Department of Epidemiology and Biostatistics, Tbilisi State Medical University, Georgia
| | - Maia Kereselidze
- Medical Statistics Department, National Center for Disease Control and Public Health, Tbilisi, Georgia
| | - Konstantin Kazanjan
- Medical Statistics Department, National Center for Disease Control and Public Health, Tbilisi, Georgia
| | - Saba Zhizhilashvili
- Department of Epidemiology and Biostatistics, Tbilisi State Medical University, Georgia
| | - Rifat Atun
- Department of Global Health & Population, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA; Department of Health Policy & Management, Harvard T.H. Chan School of Public Health, Harvard University, Boston MA, USA
| | - Michel P Coleman
- Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK; Cancer Division, University College London Hospitals NHS Foundation Trust, London, UK
| | - Claudia Allemani
- Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
| |
Collapse
|
7
|
Auguste A, Gathere S, Pinheiro PS, Adebamowo C, Akintola A, Alleyne-Mike K, Anderson SG, Ashing K, Awittor FK, Awuah B, Bhakkan B, Deloumeaux J, du Plessis M, Ekanem IOA, Ekanem U, Ezeome E, Felix N, Gachii AK, Gaete S, Gibson T, Hage R, Harrison S, Igbinoba F, Iseh K, Kiptanui E, Korir A, Lawson-Myers HD, Llanos A, Luce D, McNaughton D, Odutola M, Omonisi A, Otu T, Peruvien J, Raheem N, Roach V, Sobers N, Uamburu N, Ragin C. Heterogeneity in head and neck cancer incidence among black populations from Africa, the Caribbean and the USA: Analysis of cancer registry data by the AC3. Cancer Epidemiol 2021; 75:102053. [PMID: 34743058 PMCID: PMC8627451 DOI: 10.1016/j.canep.2021.102053] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2021] [Revised: 10/12/2021] [Accepted: 10/16/2021] [Indexed: 12/13/2022]
Abstract
BACKGROUND Africa and the Caribbean are projected to have greater increases in Head and neck cancer (HNC) burden in comparison to North America and Europe. The knowledge needed to reinforce prevention in these populations is limited. We compared for the first time, incidence rates of HNC in black populations from African, the Caribbean and USA. METHODS Annual age-standardized incidence rates (IR) and 95% confidence intervals (95%CI) per 100,000 were calculated for 2013-2015 using population-based cancer registry data for 14,911 HNC cases from the Caribbean (Barbados, Guadeloupe, Trinidad & Tobago, N = 443), Africa (Kenya, Nigeria, N = 772) and the United States (SEER, Florida, N = 13,696). We compared rates by sub-sites and sex among countries using data from registries with high quality and completeness. RESULTS In 2013-2015, compared to other countries, HNC incidence was highest among SEER states (IR: 18.2, 95%CI = 17.6-18.8) among men, and highest in Kenya (IR: 7.5, 95%CI = 6.3-8.7) among women. Nasopharyngeal cancer IR was higher in Kenya for men (IR: 3.1, 95%CI = 2.5-3.7) and women (IR: 1.5, 95%CI = 1.0-1.9). Female oral cavity cancer was also notably higher in Kenya (IR = 3.9, 95%CI = 3.0-4.9). Blacks from SEER states had higher incidence of laryngeal cancer (IR: 5.5, 95%CI = 5.2-5.8) compared to other countries and even Florida blacks (IR: 4.4, 95%CI = 3.9-5.0). CONCLUSION We found heterogeneity in IRs for HNC among these diverse black populations; notably, Kenya which had distinctively higher incidence of nasopharyngeal and female oral cavity cancer. Targeted etiological investigations are warranted considering the low consumption of tobacco and alcohol among Kenyan women. Overall, our findings suggest that behavioral and environmental factors are more important determinants of HNC than race.
Collapse
Affiliation(s)
- Aviane Auguste
- Guadeloupe Cancer Registry, University Hospital of Guadeloupe, Pointe-à-Pitre, Guadeloupe, France; African Caribbean Cancer Consortium USA.
| | - Samuel Gathere
- The National Cancer Registry, Kenya Medical Research Institute, Nairobi, Kenya; African Caribbean Cancer Consortium USA
| | - Paulo S Pinheiro
- University of Miami, Sylvester Comprehensive Cancer Center, FL, USA; African Caribbean Cancer Consortium USA
| | - Clement Adebamowo
- Department of Epidemiology and Public Health and the Institute of Human Virology, The Marlene and Stewart Greenebaum Comprehensive Cancer Centre, University of Maryland School of Medicine, Baltimore, MD, USA; Center for Bioethics and Research, Ibadan, Nigeria; Nigerian National System of Cancer Registries, Federal Ministry of Health, Abuja, Nigeria
| | - Adeola Akintola
- Center for Bioethics and Research, Ibadan, Nigeria; Nigerian National System of Cancer Registries, Federal Ministry of Health, Abuja, Nigeria
| | - Kellie Alleyne-Mike
- Cancer Centre of Trinidad and Tobago, St. James, Trinidad and Tobago; African Caribbean Cancer Consortium USA
| | - Simon G Anderson
- Barbados National Registry, The George Alleyne Chronic Disease Research Centre, Caribbean Institute for Health Research, University of the West Indies, Cave Hill, Barbados; African Caribbean Cancer Consortium USA
| | - Kimlin Ashing
- City of Hope Cancer Center, Duarte, CA, USA; African Caribbean Cancer Consortium USA
| | | | - Baffour Awuah
- Kumasi Cancer Registry, Komfo Anokye Teaching Hospital, Kumasi, Ghana; African Caribbean Cancer Consortium USA
| | - Bernard Bhakkan
- Guadeloupe Cancer Registry, University Hospital of Guadeloupe, Pointe-à-Pitre, Guadeloupe, France; African Caribbean Cancer Consortium USA
| | - Jacqueline Deloumeaux
- Guadeloupe Cancer Registry, University Hospital of Guadeloupe, Pointe-à-Pitre, Guadeloupe, France; Biological Resource Center Karubiotec™, BRIF n° KARUBIOTEC-GUA-00971, Pointe-à-Pitre, Guadeloupe; African Caribbean Cancer Consortium USA
| | - Maira du Plessis
- Department of Anatomical Sciences, St Georges University, Grenada, West Indies; African Caribbean Cancer Consortium USA
| | - Ima-Obong A Ekanem
- Nigerian National System of Cancer Registries, Federal Ministry of Health, Abuja, Nigeria; Calabar Cancer Registry, Department of Pathology, College of Medical Sciences, University of Calabar and Teaching Hospital, Calabar, Nigeria
| | - Uwemedimbuk Ekanem
- Nigerian National System of Cancer Registries, Federal Ministry of Health, Abuja, Nigeria; Department of Community Health, Faculty of Clinical Sciences, College of Health Sciences, University of Uyo/University of Uyo Teaching Hospital, Uyo, Nigeria
| | - Emmanuel Ezeome
- Nigerian National System of Cancer Registries, Federal Ministry of Health, Abuja, Nigeria; Enugu Cancer Registry, University of Nigeria Teaching Hospital, Enugu, Nigeria
| | - Nkese Felix
- Dr. Elizabeth Quamina Cancer Registry, the National Cancer Registry of Trinidad and Tobago, Mount Hope, Trinidad and Tobago
| | - Andrew K Gachii
- Department of Lab Medicine, Kenyatta National Hospital, Nairobi, Kenya; African Caribbean Cancer Consortium USA
| | - Stanie Gaete
- Biological Resource Center Karubiotec™, BRIF n° KARUBIOTEC-GUA-00971, Pointe-à-Pitre, Guadeloupe; African Caribbean Cancer Consortium USA
| | - Tracey Gibson
- Jamaica Cancer Registry, Department of Pathology, University of the West Indies, Kingston, Jamaica; African Caribbean Cancer Consortium USA
| | - Robert Hage
- Department of Anatomical Sciences, St Georges University, Grenada, West Indies; African Caribbean Cancer Consortium USA
| | - Sharon Harrison
- Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, PA, USA; African Caribbean Cancer Consortium USA
| | - Festus Igbinoba
- Nigerian National System of Cancer Registries, Federal Ministry of Health, Abuja, Nigeria; National Hospital Abuja, Abuja, Nigeria
| | - Kufre Iseh
- Nigerian National System of Cancer Registries, Federal Ministry of Health, Abuja, Nigeria; Department of Otorhinolaryngology/Head &Neck Surgery, Faculty of Clinical sciences, Usmanu Danfodiyo University/Usmanu Danfodiyo University Teaching Hospital, Sokoto, Nigeria; Population Based Cancer Registry, Usmanu Danfodiyo University Teaching Hospital, Sokoto, Nigeria
| | - Evans Kiptanui
- The National Cancer Registry, Kenya Medical Research Institute, Nairobi, Kenya
| | - Ann Korir
- The National Cancer Registry, Kenya Medical Research Institute, Nairobi, Kenya; African Caribbean Cancer Consortium USA
| | - Heather-Dawn Lawson-Myers
- Liguanea Family Dental Centre, Seymour Park, Kingston, Jamaica; African Caribbean Cancer Consortium USA
| | - Adana Llanos
- Department of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York, USA; African Caribbean Cancer Consortium USA
| | - Daniele Luce
- Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Pointe-à-Pitre, Guadeloupe, France; African Caribbean Cancer Consortium USA
| | - Dawn McNaughton
- Jamaica Cancer Registry, Department of Pathology, University of the West Indies, Kingston, Jamaica; African Caribbean Cancer Consortium USA
| | - Michael Odutola
- Nigerian National System of Cancer Registries, Federal Ministry of Health, Abuja, Nigeria; Center for Big Data Research in Health, University of New South Wales, Sydney, Australia; African Caribbean Cancer Consortium USA
| | - Abidemi Omonisi
- Nigerian National System of Cancer Registries, Federal Ministry of Health, Abuja, Nigeria; Department of Anatomic Pathology, Ekiti State University and Teaching Hospital, Ado-Ekiti, Nigeria
| | - Theresa Otu
- Nigerian National System of Cancer Registries, Federal Ministry of Health, Abuja, Nigeria; Abuja Cancer Registry, Department of Haematology and Blood Transfusion, University of Abuja Teaching Hospital, Gawgwalada, Nigeria
| | - Jessica Peruvien
- Guadeloupe Cancer Registry, University Hospital of Guadeloupe, Pointe-à-Pitre, Guadeloupe, France
| | - Nasiru Raheem
- Nigerian National System of Cancer Registries, Federal Ministry of Health, Abuja, Nigeria; Department of Pathology, Federal Medical Centre, Yola, Nigeria
| | | | - Natasha Sobers
- Barbados National Registry, The George Alleyne Chronic Disease Research Centre, Caribbean Institute for Health Research, University of the West Indies, Cave Hill, Barbados; African Caribbean Cancer Consortium USA
| | - Nguundja Uamburu
- Dental Department, Katutura State Hospital, Windhoek, Namibia; African Caribbean Cancer Consortium USA
| | - Camille Ragin
- Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, PA, USA; African Caribbean Cancer Consortium USA
| |
Collapse
|
8
|
Pilleron S, Maringe C, Charvat H, Atkinson J, Morris EJA, Sarfati D. The impact of timely cancer diagnosis on age disparities in colon cancer survival. J Geriatr Oncol 2021; 12:1044-1051. [PMID: 33863698 DOI: 10.1016/j.jgo.2021.04.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2020] [Revised: 03/01/2021] [Accepted: 04/07/2021] [Indexed: 11/20/2022]
Abstract
OBJECTIVE We described the role of patient-related and clinical factors on age disparities in colon cancer survival among patients aged 50-99 using New Zealand population-based cancer registry data linked to hospitalisation data. METHOD We included 21,270 new colon cancer cases diagnosed between 1 January 2006 and 31 July 2017, followed up to end 2019. We modelled the effect of age at diagnosis, sex, ethnicity, deprivation, comorbidity, and emergency presentation on colon cancer survival by stage at diagnosis using flexible excess hazard regression models. RESULTS The excess mortality in older patients was minimal for localised cancers, maximal during the first six months for regional cancers, the first eighteen months for distant cancers, and over the three years for missing stages. The age pattern of the excess mortality hazard varied according to sex for distant cancers, emergency presentation for regional and distant cancers, and comorbidity for cancer with missing stages. Ethnicity and deprivation did not influence age disparities in colon cancer survival. CONCLUSION Factors reflecting timeliness of cancer diagnosis most affected age-related disparities in colon cancer survival, probably by impacting treatment strategy. Because of the high risk of poor outcomes related to treatment in older patients, efforts made to improve earlier diagnosis in older patients are likely to help reduce age disparities in colon cancer survival in New Zealand.
Collapse
Affiliation(s)
- Sophie Pilleron
- Dept of Public Health, School of medicine, University of Otago, Wellington, New Zealand; Nuffield Department of Population Health, University of Oxford, Big Data Institute, Old Road Campus, Oxford OX3 7LF, UK.
| | - Camille Maringe
- Inequalities in Cancer Outcomes Network, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
| | - Hadrien Charvat
- Epidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan; Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France
| | - June Atkinson
- Dept of Public Health, School of medicine, University of Otago, Wellington, New Zealand
| | - Eva J A Morris
- Nuffield Department of Population Health, University of Oxford, Big Data Institute, Old Road Campus, Oxford OX3 7LF, UK
| | - Diana Sarfati
- Dept of Public Health, School of medicine, University of Otago, Wellington, New Zealand
| |
Collapse
|
9
|
Pilleron S, Maringe C, Charvat H, Atkinson J, Morris E, Sarfati D. Age disparities in lung cancer survival in New Zealand: The role of patient and clinical factors. Lung Cancer 2021; 157:92-99. [PMID: 34006378 DOI: 10.1016/j.lungcan.2021.05.015] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2021] [Revised: 05/05/2021] [Accepted: 05/10/2021] [Indexed: 11/19/2022]
Abstract
OBJECTIVE Age is an important prognostic factor for lung cancer. However, no studies have investigated the age difference in lung cancer survival per se. We, therefore, described the role of patient-related and clinical factors on the age pattern in lung cancer excess mortality hazard by stage at diagnosis in New Zealand. MATERIALS AND METHODS We extracted 22 487 new lung cancer cases aged 50-99 (median age = 71, 47.1 % females) diagnosed between 1 January 2006 and 31 July 2017 from the New Zealand population-based cancer registry and followed up to December 2019. We modelled the effect of age at diagnosis, sex, ethnicity, deprivation, comorbidity, and emergency presentation on the excess mortality hazard by stage at diagnosis, and we derived corresponding lung cancer net survival. RESULTS The age difference in net survival was particularly marked for localised and regional lung cancers, with a sharp decline in survival from the age of 70. No identified factors influenced age disparities in patients with localised cancer. However, for other stages, females had a greater difference in survival between middle-age and older-age than males. Comorbidity and emergency presentation played a minor role. Ethnicity and deprivation did not influence age disparities in lung cancer survival. CONCLUSION Sex and stage at diagnosis were the most important factors of age disparities in lung cancer survival in New Zealand.
Collapse
Affiliation(s)
- Sophie Pilleron
- Department of Public Health, University of Otago, PO Box 7343, Wellington, New Zealand; Nuffield Department of Population Health, University of Oxford, Big Data Institute, Old Road Campus, Oxford, OX3 7LF, UK.
| | - Camille Maringe
- Inequalities in Cancer Outcomes Network, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.
| | - Hadrien Charvat
- Epidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan; Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France.
| | - June Atkinson
- Department of Public Health, University of Otago, PO Box 7343, Wellington, New Zealand.
| | - Eva Morris
- Nuffield Department of Population Health, University of Oxford, Big Data Institute, Old Road Campus, Oxford, OX3 7LF, UK. https://www.twitter.com/EJAMorris
| | - Diana Sarfati
- Department of Public Health, University of Otago, PO Box 7343, Wellington, New Zealand. https://www.twitter.com/DiSarfati
| |
Collapse
|
10
|
Abstract
INTRODUCTION Cancer prevalence (people alive on a certain date in a population who previously had a cancer diagnosis) is expected to increase in the United States and Europe due to improvements in survival and population aging. Examination of prevalence by phase of care allows us to identify subgroups of patients according to their care trajectories, thus allowing us to improve health care planning, resource allocation, and calculation of costs. METHODS A new method to estimate prevalence by phase of care using grouped data is illustrated. Prevalence is divided into 3 mutually exclusive phases: initial, continuing, and end-of-life. An application to US and Italian data is applied to prevalent cases diagnosed with colon-rectum, stomach, lung, or breast cancer. RESULTS The distribution of phase of care prevalence estimated by cancer type and sex and results from the two datasets are very similar. Most survivors are in the continuing phase; the end-of-life phase is larger for cancers with worse prognosis. All phases prevalence is generally higher in the Italian than in the US dataset, except for lung cancer in women, where prevalence proportion in the Italian dataset is 30% lower than in the United States. DISCUSSION Incidence, survival, and population age structure are the main determinants of prevalence and they can affect differences in all phases of prevalence, as well as in discrete phases. Incidence is the most influential determinant. Ours is the first study that compares prevalence by phase of care between two populations in Italy and the United States. Despite great differences in health care management in the two countries, we found extremely similar distribution of survivors by phase of care for most cancer sites under study.
Collapse
Affiliation(s)
- Anna Gigli
- Institute for Research on Population and Social Policies, National Research Council, Rome, Lazio, Italy
| | - Silvia Francisci
- National Centre for Disease Prevention and Health Promotion, National Health Institute, Rome, Italy
| | | | - Aaron Hall
- Information Management Services, Calverton, MD, USA
| | - Mark Hachey
- Information Management Services, Calverton, MD, USA
| | - Steve Scoppa
- Information Management Services, Calverton, MD, USA
| | - Angela Mariotto
- Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA
| |
Collapse
|
11
|
Ziegenhorn HV, Frie KG, Ekanem IO, Ebughe G, Kamate B, Traore C, Dzamalala C, Ogunbiyi O, Igbinoba F, Liu B, Bauer M, Thomssen C, Parkin DM, Wickenhauser C, Kantelhardt EJ. Breast cancer pathology services in sub-Saharan Africa: a survey within population-based cancer registries. BMC Health Serv Res 2020; 20:912. [PMID: 33008380 PMCID: PMC7531092 DOI: 10.1186/s12913-020-05752-y] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2020] [Accepted: 09/21/2020] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Pathologists face major challenges in breast cancer diagnostics in sub-Saharan Africa (SSA). The major problems identified as impairing the quality of pathology reports are shortcomings of equipment, organization and insufficiently qualified personnel. In addition, in the context of breast cancer, immunohistochemistry (IHC) needs to be available for the evaluation of biomarkers. In the study presented, we aim to describe the current state of breast cancer pathology in order to highlight the unmet needs. METHODS We obtained information on breast cancer pathology services within population-based cancer registries in SSA. A survey of 20 participating pathology centres was carried out. These centres represent large, rather well-equipped pathologies. The data obtained were related to the known population and breast cancer incidence of the registry areas. RESULTS The responding pathologists served populations of between 30,000 and 1.8 million and the centres surveyed dealt with 10-386 breast cancer cases per year. Time to fixation and formalin fixation time varied from overnight to more than 72 h. Only five centres processed core needle biopsies as a daily routine. Technical problems were common, with 14 centres reporting temporary power outages and 18 centres claiming to own faulty equipment with no access to technical support. Only half of the centres carried out IHC in their own laboratory. For three centres, IHC was only accessible outside of the country and one centre could not obtain any IHC results. A tumour board was established in 13 centres. CONCLUSIONS We conclude that breast cancer pathology services ensuring state-of-the-art therapy are only available in a small fraction of centres in SSA. To overcome these limitations, many of the centres require larger numbers of experienced pathologists and technical staff. Furthermore, equipment maintenance, standardization of processing guidelines and establishment of an IHC service are needed to comply with international standards of breast cancer pathology.
Collapse
Affiliation(s)
- Hannes-Viktor Ziegenhorn
- Institute of Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, Magdeburgerstrasse 8, 06097, Halle, Germany
| | - Kirstin Grosse Frie
- Institute of Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, Magdeburgerstrasse 8, 06097, Halle, Germany
| | - Ima-Obong Ekanem
- Department of Pathology, University of Calabar, Cancer Registry, Calabar, Nigeria
- University of Calabar Teaching Hospital, Calabar, Nigeria
| | - Godwin Ebughe
- Department of Pathology, University of Calabar, Cancer Registry, Calabar, Nigeria
- University of Calabar Teaching Hospital, Calabar, Nigeria
| | - Bakarou Kamate
- Department of Pathology, University of Bamako, Bamako Cancer Registry, Bamako, Mali
| | - Cheick Traore
- Department of Pathology, University of Bamako, Bamako Cancer Registry, Bamako, Mali
| | - Charles Dzamalala
- University of Malawi College of Medicine, Cancer Registry, Blantyre, Malawi
| | - Olufemi Ogunbiyi
- University of Ibadan, Cancer registry, Ibadan, Nigeria
- University of Ibadan College of Medicine, Ibadan, Nigeria
| | | | - Biying Liu
- The African Cancer Registry Network, INCTR African Registry Program, Oxford, UK
- Nuffield Department of Population Health, University of Oxford, Oxford, UK
| | - Marcus Bauer
- Institute of Pathology, Martin-Luther-University Halle-Wittenberg, Halle, Germany
| | - Christoph Thomssen
- Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle, Germany
| | - Donald Maxwell Parkin
- The African Cancer Registry Network, INCTR African Registry Program, Oxford, UK
- Nuffield Department of Population Health, University of Oxford, Oxford, UK
- International Agency for Research on Cancer, Lyon, France
| | - Claudia Wickenhauser
- Institute of Pathology, Martin-Luther-University Halle-Wittenberg, Halle, Germany
| | - Eva Johanna Kantelhardt
- Institute of Medical Epidemiology, Biometrics and Informatics, Martin-Luther-University Halle-Wittenberg, Magdeburgerstrasse 8, 06097, Halle, Germany.
- Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle, Germany.
| |
Collapse
|
12
|
Ji J, Luo Z, Chen Y, Xu X, Li X, Liu S, Tong S. Characteristics and trends of childhood cancer in Pudong, China, 2002-2015. BMC Public Health 2020; 20:1430. [PMID: 32958056 PMCID: PMC7507240 DOI: 10.1186/s12889-020-09493-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2019] [Accepted: 09/02/2020] [Indexed: 11/15/2022] Open
Abstract
Background With the growing threat of cancer to children’s health, it is necessary to analyze characteristics and trends of childhood cancer to formulate better cancer prevention strategies. Methods Data on the 430 children with cancer during 2002–2015 were collected from the Pudong Cancer Registry, diagnosed with the International Classification of Diseases for Oncology and categorized according to the International Classification of Childhood Cancer. The incidence rate, trends over time, and survival of patients grouped by sex, age, and region were explored using the Kaplan-Meier, Cox regression, and Joinpoint Regression models. Results The crude childhood cancer incidence and world age-standardized incidence rate (ASR) were 115.1/1,000,000 and 116.3/1,000,000 person-years. The two most frequent cancers were leukemia (136/430, 31.63%, ASR, 37.8/1,000,000 person-years) and central nervous system (CNS) tumors (86/430, 20.00%, ASR, 22.9/1,000,000 person-years). Our findings indicate that the survival rate for children between 10 and 15 years of age was higher than that for 5–10; and the survival rate for children who had leukemia was higher than that of children with CNS tumors. However, the overall incidence of childhood cancer, and leukemia, CNS tumors remained relatively stable in Pudong between 2002 and 2015. Conclusions The incidence and survival rate for childhood cancer patients varied by age and cancer type. The overall trends of childhood cancer incidence remained relatively stable in Pudong from 2002 to 2015 even though socioeconomic development has been unprecedentedly fast in this region.
Collapse
Affiliation(s)
- Junqi Ji
- Department of Clinical Epidemiology and Biostatistics, Children Health Advocacy Institute, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, 1678 Dongfang Road, Shanghai, 200127, China
| | - Zheng Luo
- Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, Shanghai, China
| | - Yichen Chen
- Pudong New Area Center for Disease Control and Prevention, Fudan University Pudong Institute of Preventive Medicine, Pudong New Area, Shanghai, China
| | - Xiaoyun Xu
- Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, Shanghai, China.
| | - Xiaopan Li
- Pudong New Area Center for Disease Control and Prevention, Fudan University Pudong Institute of Preventive Medicine, Pudong New Area, Shanghai, China.
| | - Shijian Liu
- Department of Clinical Epidemiology and Biostatistics, Children Health Advocacy Institute, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, 1678 Dongfang Road, Shanghai, 200127, China. .,School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
| | - Shilu Tong
- Department of Clinical Epidemiology and Biostatistics, Children Health Advocacy Institute, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, 1678 Dongfang Road, Shanghai, 200127, China.,School of Public Health, Institute of Environment and Population Health, Anhui Medical University, Hefei, China.,Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.,School of Public Health and Social Work, Queensland University of Technology, Brisbane, Australia
| |
Collapse
|
13
|
Zhu C, You Y, Liu S, Ji Y, Yu J. A Nomogram to Predict Distant Metastasis for Patients with Esophageal Cancer. Oncol Res Treat 2019; 43:2-9. [PMID: 31715610 DOI: 10.1159/000503613] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2019] [Accepted: 09/18/2019] [Indexed: 11/19/2022]
Abstract
BACKGROUND Distant metastasis of esophageal cancer (EC) is prone to be neglected, so it is necessary to screen out the high-risk population for more sensitive and rigorous pretreatment imaging evaluations. OBJECTIVE The aim of this study was to evaluate the risk factors for distant metastasis in patients with EC and to construct a clinical nomogram. METHODS Eligible patients diagnosed from 2010 to 2015 were selected from the Surveillance, Epidemiology and End Results (SEER) database. Multivariable logistic regression analysis was applied to establish a prediction nomogram. Discrimination, calibration, clinical usefulness, and reproducibility were assessed by C-index, receiver-operating characteristic curve/the area under the curve (AUC), calibration plot, decision curve analysis (DCA), and bootstrapping validation. DCA was also used to compare the novel model with the conventional predictive methods. RESULTS A total of 9,026 patients were included for analysis. The nomogram incorporated the predictors: age, sex, race, grade, T stage, N stage, histology, tumor location, and pathological grading. The prediction model presented good discrimination with an AUC of 0.738 and a concordance index of 0.747 (95% confidence interval: 0.734-0.760), which was confirmed to be 0.745 through bootstrapping validation. Calibration plot and DCA showed satisfactory calibration and good net benefit, respectively. Comparing with the conventional prediction methods, the nomogram yielded superior net benefit. CONCLUSIONS We constructed and validated a novel nomogram to help clinicians access the risk of distant metastasis in patients with EC.
Collapse
Affiliation(s)
- Chao Zhu
- Clinical Medical College, Shandong University, Jinan, China.,Department of Oncology, Qingdao Central Hospital, Qingdao, China
| | - Yunhong You
- Department of Oncology, Qingdao Central Hospital, Qingdao, China
| | - Shichao Liu
- Department of Oncology, Qingdao Central Hospital, Qingdao, China
| | - Youxin Ji
- Department of Oncology, Qingdao Central Hospital, Qingdao, China
| | - Jinming Yu
- Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China,
| |
Collapse
|
14
|
Botta L, Dal Maso L, Guzzinati S, Panato C, Gatta G, Trama A, Rugge M, Tagliabue G, Casella C, Caruso B, Michiara M, Ferretti S, Sensi F, Tumino R, Toffolutti F, Russo AG, Caiazzo AL, Mangone L, Mazzucco W, Iacovacci S, Ricci P, Gola G, Candela G, Sardo AS, De Angelis R, Buzzoni C, Capocaccia R. Changes in life expectancy for cancer patients over time since diagnosis. J Adv Res 2019; 20:153-159. [PMID: 31467707 PMCID: PMC6710558 DOI: 10.1016/j.jare.2019.07.002] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2019] [Revised: 07/12/2019] [Accepted: 07/12/2019] [Indexed: 11/16/2022] Open
Abstract
Research question: how cancer impacts on LE changes during patients’ entire life LE increased in patients surviving the first years and decreasing thereafter. Patients’ LE in the long-term approached but seldom reached the general population’s LE. This method describes when cancer survivors’ excess risk of death became negligible. Life expectancy indicator is easy to be understood and interpreted by patients.
The aims of this study were to provide life expectancy (LE) estimates of cancer patients at diagnosis and LE changes over time since diagnosis to describe the impact of cancer during patients' entire lives. Cancer patients' LE was calculated by standard period life table methodology using the relative survival of Italian patients diagnosed in population-based cancer registries in 1985–2011 with follow-up to 2013. Data were smoothed using a polynomial model and years of life lost (YLL) were calculated as the difference between patients' LE and that of the age- and sex-matched general population. The YLL at diagnosis was highest at the youngest age at diagnosis, steadily decreasing thereafter. For patients diagnosed at age 45 years, the YLL was above 20 for lung and ovarian cancers and below 6 for thyroid cancer in women and melanoma in men. LE progressively increased in patients surviving the first years, decreasing thereafter, to approach that of the general population. YLL in the long run mainly depends on attained age. Providing quantitative data is essential to better define clinical follow-up and plan health care resource allocation. These results help assess when the excess risk of death from tumour becomes negligible in cancer survivors.
Collapse
Affiliation(s)
- Laura Botta
- Evaluative Epidemiology Unit, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy
| | - Luigino Dal Maso
- Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, PN, Italy
| | | | - Chiara Panato
- Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, PN, Italy
| | - Gemma Gatta
- Evaluative Epidemiology Unit, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy
| | - Annalisa Trama
- Evaluative Epidemiology Unit, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy
| | - Massimo Rugge
- Veneto Tumor Registry, Azienda Zero, 35131 Padua, Italy
| | - Giovanna Tagliabue
- Lombardy Cancer Registry, Varese Province, Cancer Registry Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy
| | - Claudia Casella
- Liguria Cancer Registry, Clinical Epidemiology, Ospedale Policlinico San Martino IRCCS, 16132 Genova, Italy
| | - Bianca Caruso
- Modena Cancer Registry, Public Health Department, AUSL di Modena, 41126 Modena, Italy
| | - Maria Michiara
- Parma Cancer Registry, Oncology Unit, Azienda Ospedaliera Universitaria di Parma, 43100 Parma, Italy
| | - Stefano Ferretti
- Ferrara Cancer Registry, University of Ferrara, Local Health Authority Ferrara, 44121 Ferrara, Italy
| | - Flavio Sensi
- North Sardinia Cancer Registry, Azienda Regionale per la Tutela della Salute, 07100 Sassari, Italy
| | - Rosario Tumino
- Cancer Registry for the Provinces of Caltanisetta and Ragusa, Dipartimento di Prevenzione Medica, Azienda Sanitaria Provinciale (ASP) Ragusa, 97100 Ragusa, Italy
| | - Federica Toffolutti
- Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, PN, Italy
| | - Antonio Giampiero Russo
- Cancer Registry of Milan, Epidemiology Unit, Agency for Health Protection of Milan, 20122 Milan, Italy
| | - Anna Luisa Caiazzo
- Cancer Registry of Salerno Province, Azienda Sanitaria Provinciale (ASP) Salerno, 84014 Nocera Inferiore, Italy
| | - Lucia Mangone
- Epidemiology Unit, Azienda USL-IRCCS di Reggio Emilia, 42100 Reggio Emilia, Italy
| | - Walter Mazzucco
- Sciences for Health Promotion (PROSAMI) Department, University of Palermo, and Clinical Epidemiology and Cancer Registry Unit, Palermo University Hospital "P. Giaccone", 90127 Palermo, Italy
| | - Silvia Iacovacci
- Cancer Registry of Latina Province, Direzione Azienda AUSL, Centro Direzionale Latina Fiori, 04100 Latina, Italy
| | - Paolo Ricci
- Mantova Cancer Registry, Epidemiology Unit, Agenzia di Tutela della Salute (ATS) della Val Padana, 46100 Mantova, Italy
| | - Gemma Gola
- Como Cancer Registry, UOC Epidemiologia-ATS Insubria, 21100 Varese, Italy
| | - Giuseppa Candela
- Trapani Cancer Registry, Dipartimento di Prevenzione della Salute, Servizio Sanitario Regionale Sicilia, Azienda Sanitaria Provinciale (ASP), 91100 Trapani, Italy
| | - Antonella Sutera Sardo
- Catanzaro Cancer Registry, Servizio di Epidemiologia e Statistica Sanitaria, Azienda Sanitaria Provinciale (ASP) Catanzaro, 88100 Catanzaro, Italy
| | - Roberta De Angelis
- Unit of Cancer Epidemiology and Genetics, Department of Oncology and Molecular Medicine, ISTITUTO SUPERIORE DI SANITA' (Italian National Institute of Health), 00161 Rome, Italy
| | - Carlotta Buzzoni
- Tuscany Cancer Registry, Clinical and Descriptive Epidemiology Unit, Cancer Prevention and Research Institute (ISPRO), 50139 Florence, Italy.,AIRTUM Database, Registro Tumori Toscano, Istituto per lo Studio e la Prevenzione Oncologica, SC Epidemiologia Clinica, 50139 Florence, Italy
| | | | | |
Collapse
|
15
|
Jooste V, Manfredi S, Napoleon M, Drouillard A, Marref I, Bedenne L, Faivre J, Bouvier AM. Patterns of care and outcomes in oesophageal cancer. Dig Liver Dis 2018; 50:1238-1243. [PMID: 30126823 DOI: 10.1016/j.dld.2018.07.011] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/22/2018] [Revised: 06/26/2018] [Accepted: 07/12/2018] [Indexed: 12/11/2022]
Abstract
BACKGROUND The optimal treatment for oesophageal cancer is a matter of debate. The aim of this study was to describe patterns of care and survival in a well-defined population for squamous cell carcinoma (SCC) and adenocarcinoma (AC) of the oesophagus. DESIGN Data were provided by the Digestive Cancer Registry of Burgundy (France). Recurrence, excess mortality and net survival were calculated. RESULTS Among non-metastatic patients, the proportion of patients resected for cure decreased between 2004 and 2013 from 16% to 9% for SCC and 48% to 22% for AC. The administration of chemoradiation increased from 45 to 53% for SCC and 21 to 30% for AC. A complete clinical response to chemoradiation was reported in 40% of the patients. Five-year net survival did not vary according to histology. It was 55% in the selected group of patients resected for cure, 44% in patients treated with chemoradiation with a complete clinical response. In multivariate analysis, treatment modality only was associated with survival. In metastatic patients, 3-year net survival was 14% for those treated with chemoradiation. CONCLUSION Chemoradiation has become the most frequently administered treatment. Cancelling or postponing surgery after chemoradiation with complete response should be assessed by a randomized clinical trial.
Collapse
Affiliation(s)
- Valerie Jooste
- Digestive Cancer Registry of Burgundy, INSERM, LNC UMR1231, University 'Bourgogne Franche-Comté', Dijon-Bourgogne University Hospital, Dijon, France
| | - Sylvain Manfredi
- Digestive Cancer Registry of Burgundy, INSERM, LNC UMR1231, University 'Bourgogne Franche-Comté', Dijon-Bourgogne University Hospital, Dijon, France
| | - Marie Napoleon
- Digestive Cancer Registry of Burgundy, INSERM, LNC UMR1231, University 'Bourgogne Franche-Comté', Dijon-Bourgogne University Hospital, Dijon, France
| | - Antoine Drouillard
- Digestive Cancer Registry of Burgundy, INSERM, LNC UMR1231, University 'Bourgogne Franche-Comté', Dijon-Bourgogne University Hospital, Dijon, France
| | - Imene Marref
- Digestive Cancer Registry of Burgundy, INSERM, LNC UMR1231, University 'Bourgogne Franche-Comté', Dijon-Bourgogne University Hospital, Dijon, France
| | - Laurent Bedenne
- Digestive Cancer Registry of Burgundy, INSERM, LNC UMR1231, University 'Bourgogne Franche-Comté', Dijon-Bourgogne University Hospital, Dijon, France
| | - Jean Faivre
- Digestive Cancer Registry of Burgundy, INSERM, LNC UMR1231, University 'Bourgogne Franche-Comté', Dijon-Bourgogne University Hospital, Dijon, France
| | - Anne-Marie Bouvier
- Digestive Cancer Registry of Burgundy, INSERM, LNC UMR1231, University 'Bourgogne Franche-Comté', Dijon-Bourgogne University Hospital, Dijon, France.
| |
Collapse
|
16
|
Manfredi S, Jooste V, Gay C, Faivre J, Drouillard A, Bouvier AM. Time trends in colorectal cancer early postoperative mortality. A French 25-year population-based study. Int J Colorectal Dis 2017; 32:1725-31. [PMID: 29046951 DOI: 10.1007/s00384-017-2918-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 10/09/2017] [Indexed: 02/04/2023]
Abstract
BACKGROUND Postoperative mortality after resection of colorectal cancer is an important issue. The aim of this study was to assess early postoperative mortality in a well-defined French population. METHODS Data on 30- and 90-day postoperative mortality after resection for colorectal cancer were extracted from the digestive cancer registry of Burgundy. Time trends of postoperative mortality between 1989 and 2013 were described for the large population. Case-control studies (death within 30 or 90 days = cases, alive at 90 days = controls) focused on the association between postoperative mortality and surgical approach, obesity and other comorbidities over the last [2010-2013] period, using conditional logistic regressions. RESULTS Among the 11,448 concerned patients, 30- and 90-day postoperative mortalities were 4.9 and 7.2%. Thirty-day operative mortality decreased from 7.2% (1989-1993) to 4.4% (2010-2013; p < 0.001) for colon cancer and from 4.2 to 3.3% for rectal cancer (NS). Diagnosis before 1997, male gender, advanced age, emergency surgery and palliative resection were associated with a significantly higher 30- and 90-day mortality rate. The univariate risk of mortality was two to three times higher for conventional open laparotomy and conversion than for laparoscopy-assisted surgery. The surgical approach was no longer significant in multivariate analysis. Emergency surgery and comorbidities were associated with higher 30- and 90-day postoperative mortality, whereas obesity was not specific. CONCLUSION Postoperative mortality after colorectal resection decreased over time. Surgical approach had no influence on early mortality. Improvement in the management of the elderly and patients with comorbidities is a challenge to reduce postoperative mortality in the future.
Collapse
|
17
|
Abstract
Rare cancers epidemiology is better known compared to the other rare diseases. Thanks to the long history of the European population-based cancer registries and to the EUROCARE huge database, the burden of rare cancers has been estimated the European (EU28) population. A considerable fraction of all cancers is represented by rare cancers (24%). They are a heterogeneous group of diseases, but they share similar problems: uncertainty of diagnosis, lack of therapies, poor research opportunities, difficulties in clinical trials, lack of expertise and of centres of reference. This paper analyses the major epidemiological indicators of frequency (incidence and prevalence) and outcome (5-year survival) of all rare cancers combined and of selected rare cancers that will be in depth treated in this monographic issue. Source of the results is the RARECAREnet search tool, a database publicly available. Disparities both in incidence and survival, and consequently in prevalence of rare cancers were reported across European countries. Major differences were shown in outcome: 5-year relative survival for all rare cancers together, adjusted by age and case-mix, varied from 55% or more (Italy, Germany, Belgium and Iceland) and less than 40% (Bulgaria, Lithuania and Slovakia). Similarly, for all the analyzed rare cancers, a large survival gap was observed between the Eastern and the Nordic and Central European regions. Dramatic geographical variations were assessed for curable cancers like testicular and non epithelial ovarian cancers. Geographical difference in the annual age-adjusted incidence rates for all rare cancers together varied between >140 per 100,000 (Italy, Scotland, France, Germany, and Switzerland) and <100 (Finland, Portugal, Malta, and Poland). Prevalence, the major indicator of public health resources needs, was about 7-8 times larger than incidence. Most of rare cancers require complex surgical treatment, thus a multidisciplinary approach is essential and treatment should be provided in centres of expertise and/or in networks including expert centres. Networking is the most appropriate answer to the issues pertaining to rare cancers. Actually, in Europe, an opportunity to improve outcome and reduce disparities is provided by the creation of the European Reference Networks for rare diseases (ERNs). The Joint Action of rare cancers (JARC) is a major European initiative aimed to support the mission of the ERNs. The role of population based cancer registries still remains crucial to describe rare cancers management and outcome in the real word and to evaluate progresses made at the country and at the European level.
Collapse
Affiliation(s)
- G Gatta
- Evaluative Epidemiology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
| | - A Trama
- Evaluative Epidemiology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy
| | - R Capocaccia
- Evaluative Epidemiology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy
| |
Collapse
|
18
|
Baioni E, Scanziani E, Vincenti MC, Leschiera M, Bozzetta E, Pezzolato M, Desiato R, Bertolini S, Maurella C, Ru G. Estimating canine cancer incidence: findings from a population-based tumour registry in northwestern Italy. BMC Vet Res 2017; 13:203. [PMID: 28659149 PMCID: PMC5490209 DOI: 10.1186/s12917-017-1126-0] [Citation(s) in RCA: 46] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2017] [Accepted: 06/21/2017] [Indexed: 11/25/2022] Open
Abstract
Background Canine cancer registry data can be put to good use in epidemiological studies. Quantitative comparison of tumour types may reveal unusual cancer frequencies, providing directions for research and generation of hypotheses of cancer causation in a specific area, and suggest leads for identifying risk factors. Here we report canine cancer incidence rates calculated from a population-based registry in an area without any known specific environmental hazard. Results In its 90 months of operation from 2001 to 2008 (the observation period in this study), the population-based Piedmont Canine Cancer Registry collected data on 1175 tumours confirmed by histopathological diagnosis. The incidence rate was 804 per 100,000 dog-years for malignant tumours and 897 per 100,000 dog-years for benign tumours. Higher rates for all cancers were observed in purebred dogs, particularly in Yorkshire terrier and Boxer. The most prevalent malignant neoplasms were cutaneous mastocytoma and hemangiopericytoma, and mammary gland complex carcinoma and simplex carcinoma. Conclusions The Piedmont canine cancer registry is one of few of its kind whose operations have been consistently supported by long-term public funding. The registry-based cancer incidence rates were estimated with particular attention to the validity of data collection, thus minimizing the potential for bias. The findings on cancer incidence rates may provide a reliable reference for comparison studies. Researches conducted on dogs, used as sentinels for community exposure to environmental carcinogens, can be useful to detect excess risks in the incidence of malignant tumours in the human population.
Collapse
Affiliation(s)
- Elisa Baioni
- Biostatistics, Epidemiology and Risk Analysis Unit, Istituto Zooprofillattico Sperimentale del Piemonte, Liguria e Valle d'Aosta, Via Bologna 148, 10154, Torino, Italy.
| | - Eugenio Scanziani
- Department of Veterinary Science and Veterinary Public Health, Università degli Studi di Milano, Milan, Italy
| | | | | | - Elena Bozzetta
- Histopathology Unit, Istituto Zooprofillattico Sperimentale del Piemonte, Liguria e Valle d'Aosta, Torino, Italy
| | - Marzia Pezzolato
- Histopathology Unit, Istituto Zooprofillattico Sperimentale del Piemonte, Liguria e Valle d'Aosta, Torino, Italy
| | - Rosanna Desiato
- Biostatistics, Epidemiology and Risk Analysis Unit, Istituto Zooprofillattico Sperimentale del Piemonte, Liguria e Valle d'Aosta, Via Bologna 148, 10154, Torino, Italy
| | - Silvia Bertolini
- Biostatistics, Epidemiology and Risk Analysis Unit, Istituto Zooprofillattico Sperimentale del Piemonte, Liguria e Valle d'Aosta, Via Bologna 148, 10154, Torino, Italy
| | - Cristiana Maurella
- Biostatistics, Epidemiology and Risk Analysis Unit, Istituto Zooprofillattico Sperimentale del Piemonte, Liguria e Valle d'Aosta, Via Bologna 148, 10154, Torino, Italy
| | - Giuseppe Ru
- Biostatistics, Epidemiology and Risk Analysis Unit, Istituto Zooprofillattico Sperimentale del Piemonte, Liguria e Valle d'Aosta, Via Bologna 148, 10154, Torino, Italy
| |
Collapse
|
19
|
Robinson JR, Newcomb PA, Hardikar S, Cohen SA, Phipps AI. Stage IV colorectal cancer primary site and patterns of distant metastasis. Cancer Epidemiol 2017; 48:92-95. [PMID: 28437692 DOI: 10.1016/j.canep.2017.04.003] [Citation(s) in RCA: 52] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2016] [Revised: 04/02/2017] [Accepted: 04/04/2017] [Indexed: 12/12/2022]
Abstract
BACKGROUND Although colorectal cancer (CRC) usually metastasizes to the liver and/or lungs, factors influencing the anatomic pattern of metastases remain poorly understood. METHODS We assessed the relationship between primary CRC site and pattern of synchronous metastasis among 1202 individuals diagnosed with incident metastatic CRC between 2010 and 2014 and identified through the Seattle-Puget Sound Surveillance, Epidemiology, and End Results (SEER) registry. Polytomous logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) for the association between primary tumor site and synchronous metastatic pattern. RESULTS Compared to patients with proximal colon primaries, patients with rectal primaries were more likely to present with lungs-only or liver and lungs metastases versus liver-only metastases (ORlungs-onlyvs.liver-only: 2.39, 95% CI: 1.35-4.24, ORliver+lungsvs.liver-only: 2.20, 95% CI: 1.46-3.32). CONCLUSION These findings suggest that patients with rectal primaries are more likely than patients with colon primaries to present with synchronous lung metastases.
Collapse
Affiliation(s)
- Jamaica R Robinson
- Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle WA, 98109, USA; Department of Epidemiology, University of Washington, 1959 NE Pacific St., Health Sciences Building, F-262, Seattle, WA, 98195, USA.
| | - Polly A Newcomb
- Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle WA, 98109, USA; Department of Epidemiology, University of Washington, 1959 NE Pacific St., Health Sciences Building, F-262, Seattle, WA, 98195, USA.
| | - Sheetal Hardikar
- Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle WA, 98109, USA; Department of Epidemiology, University of Washington, 1959 NE Pacific St., Health Sciences Building, F-262, Seattle, WA, 98195, USA.
| | - Stacey A Cohen
- Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle WA, 98109, USA; Department of Medicine, University of Washington, 1959 NE Pacific St., Health Sciences Building, RR-512, Seattle, WA, 98195, USA.
| | - Amanda I Phipps
- Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle WA, 98109, USA; Department of Epidemiology, University of Washington, 1959 NE Pacific St., Health Sciences Building, F-262, Seattle, WA, 98195, USA.
| |
Collapse
|
20
|
Weir HK, Johnson CJ, Ward KC, Coleman MP. The effect of multiple primary rules on cancer incidence rates and trends. Cancer Causes Control 2016; 27:377-90. [PMID: 26809509 PMCID: PMC5851446 DOI: 10.1007/s10552-016-0714-9] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2015] [Accepted: 01/08/2016] [Indexed: 12/13/2022]
Abstract
PURPOSE An examination of multiple primary cancers can provide insight into the etiologic role of genes, the environment, and prior cancer treatment on a cancer patient's risk of developing a subsequent cancer. Different rules for registering multiple primary cancers (MP) are used by cancer registries throughout the world making data comparisons difficult. METHODS We evaluated the effect of SEER and IARC/IACR rules on cancer incidence rates and trends using data from the SEER Program. We estimated age-standardized incidence rate (ASIR) and trends (1975-2011) for the top 26 cancer categories using joinpoint regression analysis. RESULTS ASIRs were higher using SEER compared to IARC/IACR rules for all cancers combined (3 %) and, in rank order, melanoma (9 %), female breast (7 %), urinary bladder (6 %), colon (4 %), kidney and renal pelvis (4 %), oral cavity and pharynx (3 %), lung and bronchus (2 %), and non-Hodgkin lymphoma (2 %). ASIR differences were largest for patients aged 65+ years. Trends were similar using both MP rules with the exception of cancers of the urinary bladder, and kidney and renal pelvis. CONCLUSIONS The choice of multiple primary coding rules effects incidence rates and trends. Compared to SEER MP coding rules, IARC/IACR rules are less complex, have not changed over time, and report fewer multiple primary cancers, particularly cancers that occur in paired organs, at the same anatomic site and with the same or related histologic type. Cancer registries collecting incidence data using SEER rules may want to consider including incidence rates and trends using IARC/IACR rules to facilitate international data comparisons.
Collapse
Affiliation(s)
- Hannah K Weir
- Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 4770 Buford Hwy. MS-F76, Atlanta, GA, 30341, USA.
| | | | - Kevin C Ward
- Georgia Center for Cancer Statistics, Emory University, Atlanta, GA, USA
| | | |
Collapse
|
21
|
Barbosa IR, Bernal Pérez MM, Costa ÍCC, Jerez-Roig J, Souza DLBD. [Survival of lung cancer patients treated at a referral hospital in Zaragoza (Spain)]. Semergen 2015; 42:380-7. [PMID: 26364135 DOI: 10.1016/j.semerg.2015.07.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2015] [Revised: 06/10/2015] [Accepted: 07/02/2015] [Indexed: 11/29/2022]
Abstract
OBJECTIVE The aim of this work is to study the survival of lung cancer patients treated at a referral hospital in Zaragoza (Spain). MATERIAL AND METHOD The Kaplan-Meier test was used to calculate observed survival. The automatic calculation of the Catalan Institute of Oncology was used to analyse relative survival. RESULTS Mean survival time was 25.74 months. There was no difference when comparing age groups (P=.151), gender (P=.369), and histological type of tumour (P=.086). Survival by stage of the disease at diagnosis revealed statistically significant differences (P<.001). Relative survival 5 years after diagnosis for the group analysed was 14%. Survival was higher for men (15.5%), in patients under 60 (16.7%) and squamous tumours (18.7%). CONCLUSIONS Survival by tumour stage was in line with the TNM Staging System for Lung Cancer. These results suggest that overall survival rate for lung cancer in Zaragoza remains very low in the long term, and this depends on the stage of the disease at diagnosis.
Collapse
Affiliation(s)
- I R Barbosa
- Universidade Federal do Rio Grande do Norte, Natal, Brasil
| | | | - Í C C Costa
- Universidade Federal do Rio Grande do Norte, Natal, Brasil
| | - J Jerez-Roig
- Universidade Federal do Rio Grande do Norte, Natal, Brasil
| | - D L B de Souza
- Universidade Federal do Rio Grande do Norte, Natal, Brasil.
| |
Collapse
|
22
|
El Mistiri M, Salati M, Marcheselli L, Attia A, Habil S, Alhomri F, Spika D, Allemani C, Federico M. Cancer incidence, mortality, and survival in Eastern Libya: updated report from the Benghazi Cancer Registry. Ann Epidemiol 2015; 25:564-8. [PMID: 25911981 DOI: 10.1016/j.annepidem.2015.03.012] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2014] [Revised: 03/10/2015] [Accepted: 03/13/2015] [Indexed: 02/06/2023]
Abstract
PURPOSE Despite the increasing burden of cancer occurred over recent years in the African continent, epidemiologic data from Northern Africa area have been so far sparse or absent. We present most recently available data from the Benghazi Cancer Registry concerning cancer incidence and mortality as well as the most comprehensive survival data set so far generated for cases diagnosed during 2003 to 2005 in Eastern Libya. METHODS We collected and analyzed data on cancer incidence, mortality and survival that were obtained over a 3-year study period from January 1st 2003 to December 31st 2005 from the Benghazi Cancer Registry. RESULTS A total of 3307 cancer patients were registered among residents during the study period. The world age-standardized incidence rate for all sites was 135.4 and 107.1 per 100,000 for males and females, respectively. The most common malignancies in men were cancers of lung (18.9%), colorectum (10.4%), bladder (10.1%), and prostate (9.4%); among women, they were breast (23.2%), colorectum (11.2%), corpus uteri (6.7%), and leukemia (5.1%). A total of 1367 deaths for cancer were recorded from 2003 to 2005; the leading causes of cancer death were cancers of the lung (29.3%), colorectum (8.2%), and brain (7.3%) in males and cancers of breast (14.8%), colorectum (10.6%), and liver (7%) in females. The 5-year relative survival for all cancer combined was 22.3%; survival was lower in men (19.8%) than in women (28.2%). CONCLUSIONS This study provides an updated report on cancer incidence, mortality, and survival, in Eastern Libya which may represent a useful tool for planning future interventions toward a better cancer control.
Collapse
Affiliation(s)
- Mufid El Mistiri
- Department of Oncology, Weill Cornell Medical College, Doha, Qatar
| | - Massimiliano Salati
- Department of Diagnostic, Clinical and Public Health Medicine, Modena Cancer Center, University of Modena and Reggio Emilia, Modena, Italy.
| | - Luigi Marcheselli
- Department of Diagnostic, Clinical and Public Health Medicine, Modena Cancer Center, University of Modena and Reggio Emilia, Modena, Italy
| | - Adel Attia
- Faculty of Medicine, Benghazi University, Benghazi, Libya
| | - Salah Habil
- Faculty of Medicine, Omar Al Mukhtar University, Bayda, Libya
| | - Faraj Alhomri
- Faculty of Medicine, Omar Al Mukhtar University, Bayda, Libya
| | - Devon Spika
- Cancer Research UK Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK
| | - Claudia Allemani
- Cancer Research UK Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK
| | - Massimo Federico
- Department of Diagnostic, Clinical and Public Health Medicine, Modena Cancer Center, University of Modena and Reggio Emilia, Modena, Italy
| |
Collapse
|
23
|
Bouchbika Z, Haddad H, Benchakroun N, Eddakaoui H, Kotbi S, Megrini A, Bourezgui H, Sahraoui S, Corbex M, Harif M, Benider A. Cancer incidence in Morocco: report from Casablanca registry 2005-2007. Pan Afr Med J 2013; 16:31. [PMID: 24570792 PMCID: PMC3932129 DOI: 10.11604/pamj.2013.16.31.2791] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2013] [Accepted: 07/16/2013] [Indexed: 11/11/2022] Open
Abstract
INTRODUCTION Few population-based cancer registries are in place in developing countries. In order to know the burden of cancer in Moroccan population, cancer registry initiative was put in place in the Casablanca district, the biggest city of Morocco. METHODS The data collected covers 3.6 millions inhabitant and included Casablanca city and the administrative region. RESULTS The data collected in the years 2005-07 show that the top 5 forms of cancers in women were breast (ASR: 36.4 per 100,000), cervical (15.0), thyroid (6.7), colon-rectum (5.8), and ovarian (5.3); the top 5 cancers in men were lung (25.9), prostate (13.5), bladder (8.7), colon-rectum (8.1) and non-Hodgkin lymphoma (7.2). Tumours of haematopoietic and lymphoid tissues represented 11% of all cancers (skin excluded); some presented unusual sex ratios. For breast, cervical, colorectal and thyroid cancer, respectively 57%, 42%, 28% and 60% of the cases were under 50 years of age. This was attributable to particularly low numbers of cases recorded among old people, and the young age of the general population; the observed age-specific incidences under age 50 were not higher than in western countries. Cancers at young ages were particularly common in women: 67% of the cases were under 50. Stage at diagnosis could be obtained for 82% of the breast cancer cases and was as follows: 28% local, 63% regional and 9% distant, in the absence of screening. CONCLUSION These first population-based data have provided an invaluable resource for the national cancer control plan of Morocco, and will be useful tool to its future evaluation.
Collapse
Affiliation(s)
- Zineb Bouchbika
- Department of Radiotherapy-oncology, Ibn Rochd University Hospital, Casablanca, Hassan II University, Morocco
| | - Houssam Haddad
- Department of Radiotherapy-oncology, Ibn Rochd University Hospital, Casablanca, Hassan II University, Morocco
| | - Nadia Benchakroun
- Department of Radiotherapy-oncology, Ibn Rochd University Hospital, Casablanca, Hassan II University, Morocco
| | - Houda Eddakaoui
- Department of Radiotherapy-oncology, Ibn Rochd University Hospital, Casablanca, Hassan II University, Morocco
| | - Souad Kotbi
- Registry team, Regional Directorate of Health of Casablanca, Morocco
| | - Anis Megrini
- Registry team, Regional Directorate of Health of Casablanca, Morocco
| | - Hanane Bourezgui
- Department of Radiotherapy-oncology, Ibn Rochd University Hospital, Casablanca, Hassan II University, Morocco
| | - Souha Sahraoui
- Department of Radiotherapy-oncology, Ibn Rochd University Hospital, Casablanca, Hassan II University, Morocco
| | - Marilys Corbex
- Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium
| | - Mhamed Harif
- Centre Hospitalier Mohammed VI, Marrakech, Morocco
| | - Abdellatif Benider
- Department of Radiotherapy-oncology, Ibn Rochd University Hospital, Casablanca, Hassan II University, Morocco
| |
Collapse
|